TrialThe Lancet. Oncology2020

Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.

Arthur J A T Braat et al.PubMed ↗Publisher ↗

No numbers read from the abstract.